Friday, August 17, 2018 5:55:06 PM
You write:
“There was likely little crossover impact, because only 3 patients in the entire trial received DCVax-l after recurrent surgery.”
At least one patient received DCVAX-L before recurrent surgery.
Love and Bright Light for Sunday Dennis
March 1, 2017
·
Lots has happened in the past few months. At the end of October, Sunday had another brain surgery to remove the mass and results came back as another tumour. The surgeon thought he was able to remove most or all of the tumour, however Sunday was left with loss of peripheral vision in her left eye and numbness on her left side, effecting her arm and leg. The hopes was that once the swelling went down everything would return to normal. Moving forward with treatment, her oncologist recommended a cocktail of drugs to include a drug that prevents tumour cells from making blood vessels, called Avastin, in combination with chemotherapy. Sunday also automatically moved into the open arm of the DCVax clinical trial where she would be guaranteed to receive her vaccine. When we arrived in Seattle to begin the open arm of the clinical trial, we were informed that the shot they had for her that day was her last available vaccine and that she had been receiving her vaccine all along. Being that the tumour grew back while she was receiving the vaccine means we did not get the results they were hoping for. Then in December, after a short six week recovery mode, we jumped right into treatment mode and Sunday started with this other aggressive treatment in hopes that Avastin would starve the cells and chemo would go in and wipe it all out. We went down this last week for her most recent MRI and unfortunately did not get the news we were hoping for. The MRI showed something is growing again which means the tumour is resistant to the chemotherapy. They have taken Sunday off chemo, it was ineffective and making her really sick, but will continue with Avastin as it seems to be effective in preventing new blood vessels from forming. Her oncologist recommended she go home and through diet and exercise get her immune system as strong as she possible can. As well, to try any alternative treatments we think would be beneficial. So here we are, researching, reaching out and looking for all possible treatments that could battle this tumour and be beneficial to her immune system. We have lots of irons in the fire and are hoping so badly we find a successful treatment soon. It’s been a challenging couple of years, but Sunday continues to persevere with so much dignity, and strength and beauty and wisdom and compassion and love. She is a constant inspiration!!! Now that she’s off chemo, Sunday’s starting to get some colour back in her cheeks, has more of an appetite, is able to be up and out of bed and we’ve been going for short walks. Please keep positive thoughts, high hopes, lots of strong prayers and live in LOVE!!!
https://www.facebook.com/Love-and-Bright-Light-for-Sunday-Dennis-510613112411830/
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM